Moderately pro-establishment and promotional toward Veppanu, foregrounding ESR1-mutated VERITAC-2 results (PFS and ORR benefits) while noting non-significant PFS in the overall population, and citing regulatory milestone and company leadership positively.
FDA approves Veppanu for ESR1-mutated ER+/HER2-negative advanced breast cancer based on VERITAC-2 trial data showing a median PFS of 5 months with Veppanu vs 2.1 months with fulvestrant and an ORR of 19% vs 4% in ESR1-mutated patients, while overall population showed no significant PFS difference; Guardant360 CDx designated as companion diagnostic.
Overreliance on public medical data; cautious about spin.
2026 © Helium Trades
Privacy Policy & Disclosure
* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy
of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions,
you should consult a financial expert before engaging in any transaction.
